KDR and thyroid gland carcinoma: The drugs presented in Table 2, used in the treatment of various types of thyroid cancer (TC), primarily serve to inhibit the expression of mutated genes (ALK, BRAFV600E, c-MET, EGFR, FGFR1–4, mTOR, NTRK, PDGFR, RET, ROS1, VEGFR, VEGFR1–3, and VEGFR2/3), block the interaction of key protein units, and demonstrate antiangiogenic effects (e.g., creatine kinase inhibitors).